DOI: 10.1161/STROKEAHA.117.016603
,
,
PMID: 28283608
Issn Print: 0039-2499
Publication Date: 2017/04/01
Response by Hänggi and Macdonald to Letter Regarding Article, “Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])”
Daniel Hänggi; R. Loch Macdonald
Checking for direct PDF access through Ovid |
Abstract
Abstract unavailable for this article.